The english version of the website is under development. Wherever text appears in Greek, it means it has not been translated yet.

Publications

Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.

Export 35 results:
Author Title Type [ Year(Asc)]
Filters: Author is Katsikis, Ilias  [Clear All Filters]
2014
Polyzos, S. A., Goulis D. G., Kountouras J., Mintziori G., Chatzis P., Papadakis E., et al. (2014).  Non-alcoholic fatty liver disease in women with polycystic ovary syndrome: assessment of non-invasive indices predicting hepatic steatosis and fibrosis.. Hormones (Athens). 13(4), 519-31.
Panidis, D., Tziomalos K., Papadakis E., Chatzis P., Kandaraki E. A., Tsourdi E. A., et al. (2014).  The role of orlistat combined with lifestyle changes in the management of overweight and obese patients with polycystic ovary syndrome.. Clin Endocrinol (Oxf). 80(3), 432-8.
Panidis, D., Tziomalos K., Papadakis E., Vosnakis C., Betsas G., Tsourdi E., et al. (2014).  Uterine volume and endometrial thickness in the early follicular phase in patients with polycystic ovary syndrome.. Endocr Pract. 20(6), 540-7.
2013
Panidis, D., Tziomalos K., Macut D., Kandaraki E. A., Tsourdi E. A., Papadakis E., et al. (2013).  Age- and body mass index-related differences in the prevalence of metabolic syndrome in women with polycystic ovary syndrome.. Gynecol Endocrinol. 29(10), 926-30.
Panidis, D., Tziomalos K., Chatzis P., Papadakis E., Delkos D., Tsourdi E. A., et al. (2013).  Association between menstrual cycle irregularities and endocrine and metabolic characteristics of the polycystic ovary syndrome.. Eur J Endocrinol. 168(2), 145-52.
Panidis, D., Tziomalos K., Papadakis E., Chatzis P., Kandaraki E. A., Tsourdi E. A., et al. (2013).  The clinical significance and primary determinants of hirsutism in patients with polycystic ovary syndrome.. Eur J Endocrinol. 168(6), 871-7.
Tziomalos, K., Katsikis I., Papadakis E., Kandaraki E. A., Macut D., & Panidis D. (2013).  Comparison of markers of insulin resistance and circulating androgens between women with polycystic ovary syndrome and women with metabolic syndrome.. Hum Reprod. 28(3), 785-93.
Vosnakis, C., Georgopoulos N. A., Rousso D., Mavromatidis G., Katsikis I., Roupas N. D., et al. (2013).  Diet, physical exercise and Orlistat administration increase serum anti-Müllerian hormone (AMH) levels in women with polycystic ovary syndrome (PCOS).. Gynecol Endocrinol. 29(3), 242-5.
Koiou, E., Tziomalos K., Katsikis I., Delkos D., Tsourdi E. A., & Panidis D. (2013).  Disparate effects of pharmacotherapy on plasma plasminogen activator inhibitor-1 levels in women with the polycystic ovary syndrome.. Hormones (Athens). 12(4), 559-66.
Panidis, D., Tziomalos K., Papadakis E., Kandaraki E. A., & Katsikis I. (2013).  The guidelines issued by the European Society for Human Reproduction and Embryology and the American Society for Reproductive Medicine regarding the induction of ovulation with metformin in patients with the polycystic ovary syndrome potentially require r. Hormones (Athens). 12(2), 192-200.
Panidis, D., Tziomalos K., Papadakis E., Vosnakis C., Chatzis P., & Katsikis I. (2013).  Lifestyle intervention and anti-obesity therapies in the polycystic ovary syndrome: impact on metabolism and fertility.. Endocrine. 44(3), 583-90.
Koiou, E., Tziomalos K., Katsikis I., Papadakis E., Kandaraki E. A., & Panidis D. (2013).  Platelet-derived microparticles in overweight/obese women with the polycystic ovary syndrome.. Gynecol Endocrinol. 29(3), 250-3.
Panidis, D., Macut D., Tziomalos K., Papadakis E., Mikhailidis K., Kandaraki E. A., et al. (2013).  Prevalence of metabolic syndrome in women with polycystic ovary syndrome.. Clin Endocrinol (Oxf). 78(4), 586-92.
2012
Panidis, D., Tziomalos K., Macut D., Delkos D., Betsas G., Misichronis G., et al. (2012).  Cross-sectional analysis of the effects of age on the hormonal, metabolic, and ultrasonographic features and the prevalence of the different phenotypes of polycystic ovary syndrome.. Fertil Steril. 97(2), 494-500.
Panidis, D., Tziomalos K., Misichronis G., Papadakis E., Betsas G., Katsikis I., et al. (2012).  Insulin resistance and endocrine characteristics of the different phenotypes of polycystic ovary syndrome: a prospective study.. Hum Reprod. 27(2), 541-9.
Koiou, E., Tziomalos K., Dinas K., Katsikis I., Kandaraki E. A., Tsourdi E., et al. (2012).  Plasma plasminogen activator inhibitor-1 levels in the different phenotypes of the polycystic ovary syndrome.. Endocr J. 59(1), 21-9.
Koiou, E., Tziomalos K., Katsikis I., Dinas K., Tsourdi E. A., Kandaraki E. A., et al. (2012).  Plasma von Willebrand factor antigen levels are elevated in the classic phenotypes of polycystic ovary syndrome.. Hormones (Athens). 11(1), 77-85.
Vosnakis, C., Georgopoulos N. A., Armeni A. K., Papadakis E., Roupas N. D., Katsikis I., et al. (2012).  Sibutramine administration decreases serum anti-Müllerian hormone (AMH) levels in women with polycystic ovary syndrome.. Eur J Obstet Gynecol Reprod Biol. 163(2), 185-9.
Koiou, E., Tziomalos K., Katsikis I., Kandaraki E. A., Kalaitzakis E., Delkos D., et al. (2012).  Weight loss significantly reduces serum lipocalin-2 levels in overweight and obese women with polycystic ovary syndrome.. Gynecol Endocrinol. 28(1), 20-4.
2011
Koiou, E., Tziomalos K., Katsikis I., Kalaitzakis E., Kandaraki E. A., Tsourdi E. A., et al. (2011).  Circulating platelet-derived microparticles are elevated in women with polycystic ovary syndrome diagnosed with the 1990 criteria and correlate with serum testosterone levels.. Eur J Endocrinol. 165(1), 63-8.
Koiou, E., Tziomalos K., Dinas K., Katsikis I., Kalaitzakis E., Delkos D., et al. (2011).  The effect of weight loss and treatment with metformin on serum vaspin levels in women with polycystic ovary syndrome.. Endocr J. 58(4), 237-46.
Panidis, D., Georgopoulos N. A., Piouka A., Katsikis I., Saltamavros A. D., Decavalas G., et al. (2011).  The impact of oral contraceptives and metformin on anti-Müllerian hormone serum levels in women with polycystic ovary syndrome and biochemical hyperandrogenemia.. Gynecol Endocrinol. 27(8), 587-92.
Koiou, E., Dinas K., Tziomalos K., Toulis K., Kandaraki E. A., Kalaitzakis E., et al. (2011).  The phenotypes of polycystic ovary syndrome defined by the 1990 diagnostic criteria are associated with higher serum vaspin levels than the phenotypes introduced by the 2003 criteria.. Obes Facts. 4(2), 145-50.
Katsikis, I., Karkanaki A., Misichronis G., Delkos D., Kandaraki E. A., & Panidis D. (2011).  Phenotypic expression, body mass index and insulin resistance in relation to LH levels in women with polycystic ovary syndrome.. Eur J Obstet Gynecol Reprod Biol. 156(2), 181-5.
Panidis, D., Katsikis I., Karkanaki A., Piouka A., Armeni A. K., & Georgopoulos N. A. (2011).  Serum anti-Müllerian hormone (AMH) levels are differentially modulated by both serum gonadotropins and not only by serum follicle stimulating hormone (FSH) levels.. Med Hypotheses. 77(4), 649-53.

Pages

Contact

Secretariat of the School of Medicine
 

Connect

School of Medicine's presence in social networks
Follow Us or Connect with us.